Feasibility evaluation of parallel administration of nanoliposomal irinotecan and levofolinate in unresectable pancreatic cancer treatment
Abstract Background Nanoliposomal irinotecan (nal-IRI) combined with levofolinate (l-LV) and fluorouracil (5-FU) is an effective second-line treatment for unresectable pancreatic cancer. The approved dosing schedule comprises sequential administration of premedication, nal-IRI (90 min), and l-LV (120 min), followed by 5-FU (46 h). This study evaluated the feasibility of parallel administration to shorten total infusion time by comparing parallel and sequential administration schedules. Methods This retrospective study included patients who received the nal-IRI regimen between June 2020 and December 2024. Patients were divided into two groups according to the administration schedule: sequential administration (June to October 2020, n = 13) and parallel administration (November 2020 to December 2024, n = 98). The primary endpoint was the incidence of grade ≥ 3 neutropenia within 90 d of treatment initiation. Results Grade ≥ 3 neutropenia occurred in 15.4% of patients in the sequential‑administration group and 39.8% in the parallel‑administration group (unadjusted odds ratio, 3.64; 95% confidence interval, 0.76–17.30; P = 0.13). The incidence in the first cycle was 7.7% and 8.2% between the groups ( P = 1.00). The incidences of other grade ≥ 3 and all-grade adverse events also did not differ significantly between the groups. The incidences of febrile neutropenia and fever did not differ significantly between the groups (febrile neutropenia: 7.7% vs. 7.1%, P = 1.00; fever: 46.2% vs. 25.5%, P = 0.18). The parallel-administration group had a disease control rate of 48.8%, which did not differ significantly from that of the sequential-administration group (33.3%; P = 0.37). Parallel administration reduced the daily bed occupancy time by approximately 150 min. Conclusions Parallel administration of nal-IRI and l-LV may be operationally feasible for improving resource efficiency in outpatient chemotherapy units; however, its comparative safety relative to sequential administration remains uncertain because of imprecision in the effect estimates.
Authors
- Mitsuru Sugawara (ORCID: https://orcid.org/0000-0001-5350-2950)
- Yoh Takekuma (ORCID: https://orcid.org/0000-0002-4325-0785)
- Kazuki Uchiyama
- Tatsuhiko Sakamoto
- Takuya Watanabe
- Yoshitaka Saito
- Yoshito Komatsu
Institutions
- Hokkaido University of Science (JP)
- Hokkaido University (JP)
- Hokkaido University Hospital (JP)
Publication Details
- Journal
- Journal of Pharmaceutical Health Care and Sciences
- Published
- 2026-11-15
- DOI
- https://doi.org/10.1186/s40780-026-00649-0
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00